|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
<b>:</b> The introduction of v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors in melanoma patients with BRAF (V600E) mutations has demonstrated significant clinical benefits.
|
31416288 |
2019 |
|
rs113488022
|
|
Head and Neck Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Conclusions:</b> The complete response observed here illustrate the role of molecular profiling in complicate clinical situation of rare head and neck cancer and the potential benefit of BRAF-targeted therapy in ameloblastoma carrying <i>BRAF</i> V600E mutation.
|
31781502 |
2019 |
|
rs113488022
|
|
Malignant Head and Neck Neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Conclusions:</b> The complete response observed here illustrate the role of molecular profiling in complicate clinical situation of rare head and neck cancer and the potential benefit of BRAF-targeted therapy in ameloblastoma carrying <i>BRAF</i> V600E mutation.
|
31781502 |
2019 |
|
rs113488022
|
|
Ameloblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
<b>Conclusions:</b> The complete response observed here illustrate the role of molecular profiling in complicate clinical situation of rare head and neck cancer and the potential benefit of BRAF-targeted therapy in ameloblastoma carrying <i>BRAF</i> V600E mutation.
|
31781502 |
2019 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
<b>Objective:</b> The COMBI-AD trial demonstrated the efficacy and safety of dabrafenib and trametinib in combination vs placebo as adjuvant treatment of patients with BRAF V600E/K mutation-positive resected Stage IIIA (lymph node metastasis >1 mm), IIIB, or IIIC melanoma.
|
31223037 |
2019 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
<b>Purpose:</b> Sixty percent of papillary thyroid cancers (PTC) have an oncogenic (V600E) BRAF mutation.
|
30065097 |
2018 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival.
|
30719102 |
2019 |
|
rs113488022
|
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival.
|
30719102 |
2019 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> V600E colorectal cancers are insensitive to RAF inhibitor monotherapy due to feedback reactivation of receptor tyrosine kinase signaling.
|
28951457 |
2017 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> V600E mutations have been successfully treated with targeted therapy in melanoma, non-small cell lung cancer, and thyroid cancer.
|
29295876 |
2018 |
|
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> V600E mutations have been successfully treated with targeted therapy in melanoma, non-small cell lung cancer, and thyroid cancer.
|
29295876 |
2018 |
|
rs113488022
|
|
Thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> V600E mutations have been successfully treated with targeted therapy in melanoma, non-small cell lung cancer, and thyroid cancer.
|
29295876 |
2018 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> V600E mutations have been successfully treated with targeted therapy in melanoma, non-small cell lung cancer, and thyroid cancer.
|
29295876 |
2018 |
|
rs113488022
|
|
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia.
|
31354304 |
2019 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
<i>BRAF</i>V600E (c.1799T>A) somatic mutation evaluation in fine needle aspiration biopsies (FNAB) is a powerful diagnostic tool in the settings of papillary thyroid cancer (PTC).
|
30374428 |
2018 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
(2018) report that chondroitin-4-sulfate, which is found in a common supplement meant to alleviate degenerative joint disorders, promotes the growth of BRAF V600E mutant melanoma.
|
29547718 |
2018 |
|
rs113488022
|
|
Follicular neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
- The morphologic similarity and RAS mutations in FAs, NIFTPs, and IE-PTC-FVs supports the genetic similarity of those follicular neoplasms in contrast to the unique presence of BRAF V600E mutations in PTC-EFGs.
|
29582677 |
2018 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
21 (78%, 57·7-91·4) of 27 patients with Val600Glu BRAF-mutant melanoma responded and 15 (56%, 35·3-74·5) had a confirmed response.
|
22608338 |
2012 |
|
rs113488022
|
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
|
23341544 |
2013 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
38.2% of human PTCs displayed high expression of AXL that positively correlated with RAI-refractoriness and disease persistence or recurrence, especially when combined with v-raf murine sarcoma viral oncogene homolog B(BRAF) V600E mutation.
|
31181609 |
2019 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
42 (37 PTC; 5 benign) surgical tissue samples were analysed for the BRAF V600E activating point mutation.
|
17298986 |
2007 |
|
rs113488022
|
|
Adenocarcinoma of colon
|
|
0.030 |
GeneticVariation
|
BEFREE |
51 cases of primary colon adenocarcinoma were stained with BRAF V600E-specific clone VE1 antibody against mutated BRAF protein.
|
27569082 |
2016 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
58% PTCs presented a genetic alteration either RET/PTC rearrangement, BRAF V599E mutation or both: three cases of PTCs (25%) presented a RET/PTC rearrangement; three cases of PTCs (25%) presented a BRAF V599E mutation and in one case (8%) both alterations were identified.
|
15859312 |
2005 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
80 (60.61%) of papillary thyroid carcinomas exhibited BRAF(V600E) mutation in a range of 7.7% to 46.3% of the total BRAF alleles.
|
25400776 |
2014 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
99 PTC and 11 nodular hyperplasia FFPE thyroid tissues are evaluated for the BRAF V600E mutation by the Idylla tests and compared with peptide nucleic acid-clamping PCR, real-time PCR and pyrosequencing.
|
27543599 |
2017 |